Akums Drugs and Pharmaceuticals Limited, a leading contract drug manufacturer, has launched vildagliptin SR and metformin SR tablets, a pioneering solution in the fight against diabetes.
Designed to cater to patients with type 2 diabetes mellitus who have found inadequate control with metformin monotherapy, this revolutionary combination promises effective glycaemic control and represents a remarkable advancement in diabetes treatment.
Vildagliptin SR and metformin SR tablets merge the potent mechanisms of vildagliptin and metformin to offer patients a comprehensive approach to managing their glycaemic levels. Vildagliptin, a well-tolerated oral dipeptidyl peptidase-4 inhibitor, stands out for its unique mechanism of action that prevents the degradation of glucagon-like peptide-1 (GLP-1). By doing so, it leads to reduced glycaemia, stimulates insulin secretion, and inhibits glucagon secretion in a glucose-dependent manner. This distinctive mode of action not only ensures effective glycaemic control but also significantly reduces the risk of hypoglycaemia and weight gain, making it especially suitable for elderly patients.
Metformin, a trusted and established medication, plays a pivotal role in diabetes management. Its mechanism of action centres around altering cellular energy metabolism, resulting in reduced glucose absorption from food, decreased glucose production by the liver, and heightened responsiveness to insulin. These attributes combine to make Metformin a potent glucose-lowering agent, further enhancing the efficacy of the vildagliptin-metformin combination.
Sanjeev Jain, joint managing director of Akums Drugs & Pharmaceuticals Ltd, expressed his enthusiasm for the launch, stating, "Our mission at Akums is to provide innovative solutions that elevate patients' quality of life. The introduction of vildagliptin SR and metformin SR tablets marks a leap forward in diabetes management, offering patients a safe and efficient means to control their glycaemic levels."
Sandeep Jain, joint managing director, provided additional insight, saying, "Our dedicated research and development team has worked diligently to create a product that meets the intricate needs of diabetes patients. The synergy of vildagliptin and metformin in sustained-release tablets not only demonstrates efficacy in reducing HbA1c and plasma glucose levels but also offers a weight-neutral profile and minimal risk of hypoglycaemia. This launch underscores our steadfast commitment to delivering healthcare solutions of the highest quality."
Vildagliptin SR and metformin SR tablets are available in four strengths: 50 mg/500 mg, 50 mg/1000 mg, 100 mg/500 mg, and 100 mg/1000 mg. These tablets have been granted regulatory approval by the Drug Controller General of India (DCGI), attesting to their safety and efficacy for patient use. PHARMABIZ.com |
